Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host

Share this page:

Title

Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host

Description

A 45-year-old man with severe antiphospholipid syndrome complicated by diffuse alveolar hemorrhage, who was receiving anticoagulation therapy, glucocorticoids, cyclophosphamide, and intermittent rituximab and eculizumab, was admitted to the hospital with fever.

Date Last Updated (Year-Month-Day)

2020-11-11

Citation

Choi, Bina, Manish C. Choudhary, James Regan, Jeffrey A. Sparks, Robert F. Padera, Xueting Qiu, Isaac H. Solomon, Hsiao-Hsuan Kuo, Julie Boucau, Kathryn Bowman, U. Das Adhikari, Marisa L. Winkler, Alisa A. Mueller, Tiffany Y. T. Hsu, Michaël Desjardins, Lindsey R. Baden, Brian T. Chan, Bruce D. Walker, Mathias Lichterfeld, Manfred Brigl, Douglas S. Kwon, Sanjat Kanjilal, Eugene T. Richardson, A. Helena Jonsson, Galit Alter, Amy K. Barczak, William P. Hanage, Xu G. Yu, Gaurav D. Gaiha, Michael S. Seaman, Manuela Cernadas, and Jonathan Z. Li. 2020. "Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host." New England Journal of Medicine.

Accessibility

Free online on NEJM

URL

https://www.nejm.org/doi/full/10.1056/NEJMc2031364

Read Online

https://www.nejm.org/doi/full/10.1056/NEJMc2031364